Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthroid Holding 75% Of Its Pre-Generic Script Share, Abbott Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Script share for the levothyroxine brand is "within our range of expectations" since AB-rated generics entered the market, CFO Freyman says. Abbott predicted generic erosion for Synthroid would be less than that for other drugs due, in part, to the product's narrow therapeutic range.

You may also be interested in...



Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Biaxin Could Benefit From Flu Vaccine Shortage Ahead Of Generic Competition

Abbott cautions that it is too early in the flu season to accurately predict the potential sales impact on the antibiotic brand, which is expected to face generic competition in May 2005. The company’s fourth quarter forecast assumes a conservative impact from the flu vaccine shortage.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel